Statements

CSRXP: BIG PHARMA BACK AT IT WITH EGREGIOUS PRICE HIKES OUTPACING INFLATION TO RING IN 2025

Jan 2, 2025

Brand Name Drug Companies Signal Business-as-Usual Approach to Price-Gouging Read More

CSRxP: PASSAGE OF CORNYN-BLUMENTHAL AND Q1/Q2 REFORMS WOULD BE POSITIVE STEPS TOWARD HOLDING BIG PHARMA ACCOUNTABLE FOR PATENT ABUSE

Dec 17, 2024

Bipartisan, Market-Based Solutions Would Crack Down on Big Pharma’s Patent Read More

CSRxP: USPTO WITHDRAWAL OF PATENT THICKET RULE ADDS TO URGENCY FOR CONGRESS TO PASS CORNYN-BLUMENTHAL

Dec 4, 2024

Lawmakers Must Act to Hold Big Pharma Accountable for Egregious Patent Abuse Read More

CSRxP STATEMENT ON SENATE JUDICIARY MARKUP OF THE PREVAIL ACT

Nov 21, 2024

Congress Should Not Further Consider Misguided Proposal That Would Enable More Read More

CSRxP APPLAUDS REINTRODUCTION OF REMEDY ACT IN U.S. SENATE 

Jul 31, 2024

Bipartisan, Market-Based Solution Would Help Crack Down on Anti-Competitive Read More

CSRXP: BIG PHARMA IS AT IT AGAIN, HIKES PRICES ON NEARLY 200 PRESCRIPTION DRUGS AS PART OF MID-YEAR INCREASES

Jul 15, 2024

Brand Name Drug Giants’ Average Price Increases for June-July Outpace Rate Read More